Compare
Nuwellis, Inc. vs Escalon Medical Corp vs CapsoVision, Inc vs Hyperfine, Inc.
| Latest fiscal year | Nuwellis, Inc. NUWE | Escalon Medical Corp ESMC | CapsoVision, Inc CV | Hyperfine, Inc. HYPR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $8.27M | $12.05M | $13.55M | $13.56M |
| Revenue growth (YoY) | -5.4% | +0.5% | +15.3% | +5.2% |
| Gross margin | 62.0% | 45.7% (computed) | 52.9% | 49.8% |
| Operating margin | -134.3% | 1.1% | -188.3% | -273.4% |
| Net margin | -211.9% | 0.9% | -186.8% | -262.3% |
| Net income | -$17.52M | $105.5K | -$25.32M | -$35.57M |
| EPS (Diluted) | -$25.39 | $0.00 | -$1.03 | -$0.43 |
| Operating cash flow | -$10.81M | $380.7K | -$22.86M | -$27.95M |
| Free cash flow | -$10.90M | $376.8K | -$22.95M | -$29.13M |
| Cash & equivalents | $1.08M | $545.8K | n/a | $35.09M |
| Total assets | $6.12M | $4.99M | $18.16M | $55.26M |
| Total liabilities | $3.49M | $3.08M | $4.90M | $14.26M |
| Shareholders' equity | $2.62M | $1.92M | $13.26M | $41.01M |
| Return on year-end equity | -667.7% | 5.5% | -190.9% | -86.8% |
| Shares outstanding | 1.69M | 7.42M | 46.87M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Nuwellis, Inc. | Escalon Medical Corp | CapsoVision, Inc | Hyperfine, Inc. |
|---|---|---|---|---|
| Latest | $8.27M Ended 2025-12-31 | $12.05M Ended 2025-06-30 | $13.55M Ended 2025-12-31 | $13.56M Ended 2025-12-31 |
| 1 year earlier | $8.74M Ended 2024-12-31 | $11.98M Ended 2024-06-30 | $11.76M Ended 2024-12-31 | $12.89M Ended 2024-12-31 |
| 2 years earlier | $8.86M Ended 2023-12-31 | $12.18M Ended 2023-06-30 | n/a | $11.03M Ended 2023-12-31 |
| 3 years earlier | $8.54M Ended 2022-12-31 | $10.70M Ended 2022-06-30 | n/a | $6.81M Ended 2022-12-31 |
| 4 years earlier | $7.92M Ended 2021-12-31 | $10.47M Ended 2021-06-30 | n/a | $1.50M Ended 2021-12-31 |